Synthetic MRI in Progressive MS: Associations with Disability

References

1. 1.↵
   1. Warntjes JBM,
   2. Leinhard OD,
   3. West J, et al

   . Rapid magnetic resonance quantification on the brain: optimization for clinical usage. Magn Reson Med 2008;60:320–29 doi:10.1002/mrm.21635 pmid:18666127

   CrossRefPubMed
2. 2.↵
   1. Granberg T,
   2. Uppman M,
   3. Hashim F, et al

   . Clinical feasibility of synthetic MRI in multiple sclerosis: a diagnostic and volumetric validation study. AJNR Am J Neuroradiol 2016;37:1023–29 doi:10.3174/ajnr.A4665 pmid:26797137

   Abstract/FREE Full Text
3. 3.↵
   1. Tanenbaum LN,
   2. Tsiouris AJ,
   3. Johnson AN, et al

   . Synthetic MRI for clinical neuroimaging: results of the Magnetic Resonance Image Compilation (MAGiC) prospective, multicenter, multireader trial. AJNR Am J Neuroradiol 2017;38:1103–10 doi:10.3174/ajnr.A5227 pmid:28450439

   Abstract/FREE Full Text
4. 4.↵
   1. Vågberg M,
   2. Lindqvist T,
   3. Ambarki K, et al

   . Automated determination of brain parenchymal fraction in multiple sclerosis. AJNR Am J Neuroradiol 2013;34:498–504 doi:10.3174/ajnr.A3262 pmid:22976234

   Abstract/FREE Full Text
5. 5.↵
   1. Cao J,
   2. Xu X,
   3. Zhu J, et al

   . Rapid quantification of global brain volumetry and relaxometry in patients with multiple sclerosis using synthetic magnetic resonance imaging. Quant Imaging Med Surg 2022;12:3104–14 doi:10.21037/qims-21-970 pmid:35655839

   CrossRefPubMed
6. 6.↵
   1. Lublin FD,
   2. Reingold SC,
   3. Cohen JA, et al

   . Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014;83:278–86

   CrossRefPubMed
7. 7.↵
   1. Tur C,
   2. Carbonell-Mirabent P,
   3. Cobo-Calvo Á, et al

   . Association of early progression independent of relapse activity with long-term disability after a first demyelinating event in multiple sclerosis. JAMA Neurol 2023;80:151–60 doi:10.1001/jamaneurol.2022.4655 pmid:36534392

   CrossRefPubMed
8. 8.↵
   1. Filippi M,
   2. Preziosa P,
   3. Langdon D, et al

   . Identifying progression in multiple sclerosis: new perspectives. Ann Neurol 2020;88:438–52 doi:10.1002/ana.25808 pmid:32506714

   CrossRefPubMed
9. 9.↵
   1. Cagol A,
   2. Schaedelin S,
   3. Barakovic M, et al

   . Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis. JAMA Neurol 2022;79:682–92 doi:10.1001/jamaneurol.2022.1025 pmid:35575778

   CrossRefPubMed
10. 10.↵
    1. Ladopoulos T,
    2. Matusche B,
    3. Bellenberg B, et al

    . Relaxometry and brain myelin quantification with synthetic MRI in MS subtypes and their associations with spinal cord atrophy. Neuroimage Clin 2022;36:103166 doi:10.1016/j.nicl.2022.103166 pmid:36081258

    CrossRefPubMed
11. 11.↵
    1. Thompson AJ,
    2. Banwell BL,
    3. Barkhof F, et al

    . Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 2018;17:162–73 doi:10.1016/S1474-4422(17)30470-2 pmid:29275977

    CrossRefPubMed
12. 12.↵
    1. Warntjes M,
    2. Engström M,
    3. Tisell A, et al

    . Modeling the presence of myelin and edema in the brain based on multi-parametric quantitative MRI. Front Neurol 2016;7:16 pmid:26925030

    CrossRefPubMed
13. 13.↵
    1. Dale AM,
    2. Fischl B,
    3. Sereno MI

    . Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage 1999;9:179–94 doi:10.1006/nimg.1998.0395 pmid:9931268

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Schmidt P,
    2. Pongratz V,
    3. Küster P, et al

    . Automated segmentation of changes in FLAIR-hyperintense white matter lesions in multiple sclerosis on serial magnetic resonance imaging. Neuroimage Clin 2019;23:101849 doi:10.1016/j.nicl.2019.101849 pmid:31085465

    CrossRefPubMed
15. 15.↵
    1. Hagiwara A,
    2. Warntjes M,
    3. Hori M, et al

    . SyMRI of the brain: rapid quantification of relaxation rates and proton density, with synthetic MRI, automatic brain segmentation, and myelin measurement. Invest Radiol 2017;52:647–57 doi:10.1097/RLI.0000000000000365 pmid:28257339

    CrossRefPubMed
16. 16.↵
    1. Absinta M,
    2. Lassmann H,
    3. Trapp BD

    . Mechanisms underlying progression in multiple sclerosis. Curr Opin Neurol 2020;33:277–85 doi:10.1097/WCO.0000000000000818 pmid:32324705

    CrossRefPubMed
17. 17.↵
    1. Wooliscroft L,
    2. Silbermann E,
    3. Cameron M, et al

    . Approaches to remyelination therapies in multiple sclerosis. Curr Treat Options Neurol 2019;21:34 doi:10.1007/s11940-019-0574-1 pmid:31250211

    CrossRefPubMed
18. 18.↵
    1. Schneider R,
    2. Matusche B,
    3. Ladopoulos T, et al

    . Quantification of individual remyelination during short-term disease course by synthetic magnetic resonance imaging. Brain Commun 2022;4:fcac172 doi:10.1093/braincomms/fcac172 pmid:35938071

    CrossRefPubMed
19. 19.↵
    1. Fisher E,
    2. Rudick RA,
    3. Simon JH, et al

    . Eight-year follow-up study of brain atrophy in patients with MS. Neurology 2002;59:1412–20 doi:10.1212/01.wnl.0000036271.49066.06 pmid:12427893

    Abstract/FREE Full Text
20. 20.↵
    1. Turner B,
    2. Lin X,
    3. Calmon G, et al

    . Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years. Mult Scler 2003;9:21–27 doi:10.1191/1352458503ms868oa pmid:12617263

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Kassubek J,
    2. Tumani H,
    3. Ecker D, et al

    . Age-related brain parenchymal fraction is significantly decreased in young multiple sclerosis patients: a quantitative MRI study. Neuroreport 2003;14:427–30 doi:10.1097/00001756-200303030-00026 pmid:12634497

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Mina Y,
    2. Azodi S,
    3. Dubuche T, et al

    . Cervical and thoracic cord atrophy in multiple sclerosis phenotypes: quantification and correlation with clinical disability. Neuroimage Clin 2021;30:102680 doi:10.1016/j.nicl.2021.102680 pmid:34215150

    CrossRefPubMed
23. 23.↵
    1. Sastre-Garriga J,
    2. Rovira A,
    3. García-Vidal A, et al

    . Spinal cord reserve in multiple sclerosis. J Neurol Neurosurg Psychiatry 2023;94:502–10 doi:10.1136/jnnp-2022-330613 pmid:36690430

    Abstract/FREE Full Text